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Background: Inborn errors of metabolism (IEM) form an important cause of movement disorders in children. The
impact of metabolic diseases and concordant movement disorders upon children’s health-related quality of life
(HRQOL) and its physical and psychosocial domains of functioning has never been investigated. We therefore
conducted a case study on the HRQOL and development of adaptive functioning in children with an IEM and a
movement disorder.
Methods: Children with co-existent IEM and movement disorders were recruited from paediatric outpatient clinics.
We systematically collected clinical data and videotaped examinations. The movement disorders were diagnosed by
a panel of specialists. The Pediatric Quality of Life Inventory 4.0 and the Vineland Adaptive Behavior Scale were used
to assess the HRQOL and adaptive functioning, respectively.
Results: We recruited 24 children (10 boys, mean age 7y 5 m). Six types of movement disorders were recognised
by the expert panel, most frequently dystonia (16/24), myoclonus (7/24) and ataxia (6/24). Mean HRQOL (49.63, SD
21.78) was significantly lower than for other chronic disorders in childhood (e.g. malignancy, diabetes mellitus,
rheumatic disease, psychiatric disorders; p <0.001) and tended to diminish with the severity of the movement
disorder. The majority of participants had delayed adaptive functioning, most evident in their activities of daily
living (51.92%, SD 27.34). Delay in adaptive functioning had a significant impact upon HRQOL (p = 0.018).
Conclusions: A broad spectrum of movement disorders was seen in patients with IEM, although only five were
receiving treatment. The overall HRQOL in this population is significantly reduced. Delay in adaptive functioning,
most frequently seen in relation to activities of daily living, and the severity of the movement disorder contribute to
this lower HRQOL. We plead for a greater awareness of movement disorders and that specialists should be asked to
diagnose and treat these wherever possible.
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Inborn errors of metabolism (IEM) form a heterogeneous
group of rare inherited disorders in which the synthesis,
metabolism, transport and/or storage of metabolites or
molecules is disturbed. These changes can affect all organs
and result in a variety of symptoms. The central nervous
system is frequently involved, with disorders often mani-
festing as epilepsy and psychomotor retardation. Move-
ment disorders, although less frequently documented,
may also be present [1,2].
IEM contribute to a significant proportion of childhood
movement disorders, classified as ataxia, hypokinetic or
hyperkinetic. The last category is further subdivided into
dystonia, myoclonus, chorea, ballism, tremor and tics. An
accurate classification is important for diagnosis, ongoing
management and treatment choices. However, there is lit-
tle data on which movement disorders are most prevalent
in IEM. In addition, identifying movement disorder sub-
types, especially in children, can be challenging as these
are often associated with secondary structural lesions.
These may also precipitate additional neurological fea-
tures e.g. spasticity, epilepsy, psychomotor retardation
or other movement disorders, resulting in a complex
clinical picture [3].
As with other chronic, disabling conditions, IEM are
likely to impair physical functioning and social participa-
tion. As a result, assessing health-related quality of life
(HRQOL) has emerged as an important outcome meas-
ure in chronic illnesses of childhood [4,5]. HRQOL com-
prises the subjective perception of the impact of a chronic
illness on physical, psychological, social and occupational
functioning and its use has been established in a broad
range of childhood conditions [6,7].
To date little is known about how much impact IEM
have on children’s HRQOL. Studies in adequately treated
phenylketonuria (PKU) report a similar HRQOL to con-
trol populations [8,9]. However, PKU is detected by
screening in the newborn period thereby allowing early
therapeutic intervention and minimizing neurological
damage. This population may therefore not be representa-
tive of all IEM as a significant number of IEM are detected
when neurological impairment has already occurred. For
example, recent papers on galactosaemia and Hunter syn-
drome (mucopolysaccharidosis type II) revealed a mark-
edly impaired HRQOL in the physical and psychosocial
domains of functioning [10,11]. To our knowledge, no
previous studies have investigated the impact of a broader
range of IEM with secondary movement disorders upon
quality of life of these patients.
IEM in children are frequently associated with develop-
mental delay in one or more domains of functioning [12].
The level of disability may vary considerably between pa-
tients, suggesting that this is an important factor when
assessing HRQOL. Consequently, adaptive functioning,defined as ‘the collection of conceptual, social and prac-
tical skills that have been learned by children in order to
function in their everyday lives’, has become an important
outcome measure [13]. Our literature search found no re-
ports combining both HRQOL and adaptive functioning
tools in assessing patients with IEM.
We systematically assessed the types of movement dis-
orders observed in a cohort of patients with an estab-
lished IEM diagnosis. We are the first to use systematic
and standardised questionnaires to assess HRQOL and
adaptive functioning, thereby highlighting areas of im-
pairment in the context of these disorders.
Methods
Participants
Participants younger than 19 years of age were recruited
between January and July 2007 from two Dutch univer-
sity medical centres (Wilhelmina Children’s Hospital,
Utrecht and Academic Medical Centre, Amsterdam). All
patients with a confirmed IEM and a suspected movement
disorder were asked to participate. After enrolment, in-
formed consent or third party assent was obtained in all
cases. The study was approved by the medical research
and ethics committees of both centres.
Data collection
All participants were assessed in their home environment
and a videotaped examination was performed using a
standard protocol. Past medical history relating to the
diagnosis of the metabolic disorder, and past and present
medical therapies and their efficacy were collected from
the clinical notes. Three movement disorder specialists
(MFC, BP, MT) were blinded to the clinical diagnosis and
asked to classify the movement disorder and its severity
according to a 5-point Likert scale based on the video-
taped examination. Severity scores ranged from 1 (min-
imal), 2 (mild), 3 (moderate), 4 (severe) to 5 (very severe).
The Dutch Generic Core Scale of the Pediatric Quality
of Life Inventory (PedsQL) 4.0 and the Vineland Adap-
tive Behavior Scale (VABS) questionnaires were completed
by the parents in each case [14]. The PedsQL was used to
determine the HRQOL. This questionnaire asks parents
to indicate to what extent the child had a problem with
each item the past month. Items are subdivided in phys-
ical (8 items; walking, running, exercise, lifting, self-care,
pain, tiredness), emotional (5 items; anxiety, sadness, an-
griness, trouble sleeping, worrying), social (5 items; getting
along, friends, teasing, keeping up with others, playing)
and school-related domains (5 items; attention, forgetting,
schoolwork, missing school because of sickness or doctor
visits). Scores were calculated by the sum of all scores di-
vided by the number of answered items. Results were
compared to parent-proxy reports of the PedsQL for other
chronic stigmatizing conditions [7,15-18].
Table 1 Demographics and details of IEM diagnosis
(n = 24)
No. of cases
Sex
Male 10
Female 14
Mean age (years, months) (SD) 7y 5 m (4y 1 m)
Metabolic diagnosis
Respiratory chain defects 5
Organic acidurias 10
Glutaric aciduria type I 4/10
Propionic acaduria 2/10
Homocystinuria 2/10
Maple syrup urine disease 1/10
Methylmalonic aciduria 1/10
Disorders of carbohydrate metabolism 1
Galactosaemia 1/1
Neurotransmitter defects 2
PTPS deficiency 1/2
AADC deficiency 1/2
Other 6
CDG 1a 3/6
AASA deficiency 1/6
MCT-8 deficiency 1/6
Nonketotic hyperglycinemia 1/6
IEM Inborn error of metabolism, AADC Aromatic amino acid decarboxylase,
AASA Alpha-aminoadipic semialdehyde, CDG Congenital disorder of glycosylation,
MCT-8 Monocarboxylate transporter 8, PTPS 6-pyruvoyl-tetrahydropterin synthase,
SD Standard deviation.
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with or without cognitive impairment, was used to de-
termine age-appropriate adaptive functioning in areas of
communication, daily living skills and socialisation [19].
The total score and scores of the three sub-domains were
converted to an estimated age of development using vali-
dated age-equivalents. Percentage of development was cal-
culated by dividing estimated age of development by
biological age. Percentage of delay was calculated by sub-
tracting the percentage of development from 100%.
Statistical analysis
Statistical analysis included Mann Whitney U and t-tests,
as well as linear regression analysis where appropriate. Re-
sults were corrected for multiple comparisons using the
Bonferroni-Holm correction.
Results
A total of 24 children were recruited (10 boys, 14 girls,
mean age 7y 5 m). This cohort contained 12 different
IEM diagnoses, with organic acidurias (11/24) and re-
spiratory chain defects (5/24) being the most common.
Table 1 presents the demographic characteristics and
IEM diagnoses. MRI data were available in 17 patients,
showing abnormalities in twelve. Most common white
matter abnormalities (5/17), atrophy (4/17) and basal
ganglia abnormalities (4/17) (Additional file 1: Table S1).
Based on videotape evaluation by the panel of movement
disorder specialists, dystonia was the most frequently ob-
served movement disorder (16/24, 10 generalised, 4 seg-
mental and 2 focal), followed by myoclonus (7/24) and
ataxia (6/24). In over one-third of cases (9/24), two or
more movement disorders were observed simultaneously
(Additional file 1: Table S1).
Disease specific therapy was provided in the majority
of the patients, mostly consisting of dietary measures
(Additional file 1: Table S1). Medical therapy for treat-
ment of the movement disorders had been prescribed in
only five cases (Figure 1): in four patients, dystonia was
the predominant movement disorder, while the fifth pa-
tient had hypokinesia with more subtle dystonia. Two
dystonic patients with Glutaric Aciduria (GA) type 1 re-
ceived trihexyphenidyl and one Methylmalonic Aciduria
patient with dystonia and orofacial dyskineias was
treated with trihexyphenidyl combined with clonazepam.
In all three cases, the parents reported a beneficial effect,
particularly in reducing the mobile component of dys-
tonia. The fourth dystonic patient, who had 6-pyruvoyl-
tetrahydropterin synthase (PTPS) deficiency, received
levodopa-carbidopa both to restore normal neurotrans-
mission of dopamine as well as minimise dystonia
symptoms. Parents reported a marked response as pa-
tient showed only a mild dystonia of the limbs during
walking with this treatment strategy. The patient with apredominant hypokinetic movement disorder had an
underlying diagnosis of Aromatic Amino Acid Decar-
boxylase (AADC) deficiency. She had previously been
treated with pramipexol and tranylcypromine, but stopped
the latter due to adverse side effects.
Health-related quality of life
PedsQL scores were found to be independent of age and
sex. When compared to control data, patients in this
study had a statistically significant lower HRQOL score
in each functional sub-domain as well as in the total
score (Table 2) [14].
When compared to published data for children with
other chronic, disabling disorders, this cohort was found
to have a significantly lower total HRQOL: malignancy
(mean 68.47, SD 19.22, t(583) = -4.17, p < 0,001), diabetes
mellitus (mean 76.62, SD 14.08, t(329) = -5.97, p < 0,001),
juvenile rheumatic disease (mean 68.73, SD 19.32,
t(379) = -4,19, p <0,001) and psychiatric disorders (mean
66.90, SD 14.00, t(329) = -3.28, p < 0.001) [7,15-17].
There was no significant difference with data for children
Figure 1 Diagrammatic representation of the number, type and treatment of movement disorders. Scheme showing the number of
movement disorders per patient, and the number of patients for each movement disorder subtype. The bottom row of boxes indicates the
number of cases receiving treatment in each subgroup.
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p = 0.721) [18].
Severity scores were available in all but one case. We
divided this study cohort based on movement disorder
severity (mild to moderate versus marked to severe) and
found a significant difference in the physical functioning
domain and total HRQOL score; those with a less severe
movement disorder reported higher quality of life scores
(Table 3).
Adaptive functioning
The mean overall delay reported for adaptive function-
ing was 51.92% (SD 27.34), suggesting a developmental
age half that of their chronological age. Delay was seen
across all three sub-domains, with the highest rates
observed in relation to daily living skills (mean 57.70%,
SD 23.80), followed by socialisation (mean 40.92%, SD
33.50) and communication (mean 38.32%, SD 38.39).
The extent of delay varied widely among the patientsTable 2 HRQOL scores of children with IEM and movement di
IEM and movement disorders n = 24 Health
Mean value (SD) Mean
Total score 49.63 (21.78) 87.60 (
Physical functioning 39.71 (24.56) 92.20 (
Emotional functioning 63.50 (23.18) 81.10 (
Social functioning 49.71 (29.18) 90.30 (
School functioning 51.29 (32.05) 82.50 (
HRQOL scores were measured on the PedsQL 4.0 Generic Core Scales. Parent proxy
scores of healthy Dutch children [14].
CI Confidence interval, IEM Inborn error of metabolism, SD Standard deviation, *sign
Bold text: statistically significant.(range 0-90.95%) and was unrelated to age or sex. Adap-
tive functioning (total VABS score) was found to have a
significant impact upon HRQOL using linear regression
analysis (F(1,22) = 7.171, p = 0.014), accounting for 24.6%
of the variance in reported HRQOL (R2 = 0.246).
After the Bonferroni-Holm correction, a more severe
movement disorder did lead to a significantly larger rela-
tive delay in daily living skills (49.00% SD 23.88 vs 71.11%
SD 19.15, U(23) = 102.50, Z = 2.489, p = 0.011). We saw
trends, but no significant differences, with communication
(23.92% SD 36.44 vs 60.03 SD 34.37, U(23) = 95.00, Z =
2.018, p = 0.046), socialisation (31.74% SD 30.93 vs 56.23
SD 35.35, U(23) = 92.50, Z = 1.859, p = 0.062) and total
adaptive functioning (43.19% SD 24.46 vs 65.72 SD 28.80,
U(23) = 96.00, Z =20.79, p = 0.039).
Discussion
We systematically assessed the types of movement dis-
order observed in a paediatric IEM population with asorders compared to scores in healthy children
y Dutch population n = 87 t-value CI 95% p-value*
value (SD)
11.00) -8.21 -28.78 to -47.16 <0.001
9.10) -10.44 -43.31 to -63.67 <0.001
17.40) -3.42 -7.38 to -27.82 <0.001
14.00) -6.57 -25.32 to -52.86 <0.001
16.30) -4.49 -17.41 to -45.01 <0.001
-reports of children with IEM and movement disorders were compared to
ificance level after Bonferroni-Holm correction for multiple comparisons.
Table 3 Comparison of HRQOL scores between patients with a less severe and more severe movement disorder
Severity of
movement disorder
Minimal to moderate n = 14 Marked to severe n = 9 U-value Z-value p-value*
Mean value (SD) Mean value (SD)
Total score 59.00 (17.92) 33.67 (19.55) 22.00 -2.60 0.009
Physical functioning 49.64 (22.28) 20.44 (18.08) 18.00 -2.84 0.003
Emotional functioning 69.57 (20.33) 54.44 (26.75) 40.00 -1.45 0.159
Social functioning 59.86 (26.24) 31.67 (27.04) 48.00 -2.21 0.028
School functioning 57.36 (29.27) 39.22 (35.52) 45.50 -1.11 0.277
HRQOL scores were measured on the PedsQL 4.0 Generic Core Scales. The total cohort was divided in two groups based on the severity of their movement
disorder, determined by the expert panel.
HRQOL Health-related quality of life, SD Standard deviation; *significance level after Bonferroni-Holm correction for multiple comparisons.
Bold text: statistically significant.
Eggink et al. Orphanet Journal of Rare Diseases 2014, 9:177 Page 5 of 7
http://www.ojrd.com/content/9/1/177broad range of underlying diagnoses. This is the first study
to use systematic and standardised tools for assessing
HRQOL and adaptive functioning in such a population.
We also analysed the influence of movement disorder
severity and how delay could impact upon overall quality
of life.
Of the domains assessing HRQOL, difficulties with
physical functioning were the most frequently reported
and formed the largest contributor to reduced quality of
life. Overall HRQOL in this population was markedly
lower than that of other chronic disabling disorders, e.g.
joint disease and diabetes, but similar to that reported in
children with cerebral palsy. A previous study analysing
HRQOL scores across a range of conditions found those
with cerebral palsy to be in the group with the most im-
paired scores [7]. Both IEM and cerebral palsy are associ-
ated with motor impairment and psychomotor retardation,
suggesting that these are likely to be important determi-
nants in overall well-being in childhood [12,20]. These re-
sults also suggest that while the impact of cerebral palsy
upon quality of life is widely acknowledged, the effect of
IEM with movement disorders is similar and deserves
wider recognition in clinical practice.
Adaptive functioning scores varied widely, with the
majority of participants demonstrating delay in at least
one domain. This likely reflects the global impact of IEM
upon cerebral functioning, rather than damage to specific
areas. The extent of the delay also varied widely across all
three domains, consistent with the large variation in cere-
bral damage reported in IEM [1]. Four patients had better
communication or socialisation skills than expected for
their age. However, these same patients were reported to
have significant delays in activities of daily living, resulting
in a large overall delay in adaptive functioning. These find-
ings demonstrate the importance of being able to perform
basic tasks upon developmental delay.
Overall, adaptive functioning and HRQOL appear to be
related; a larger delay was associated with a lower HRQOL.
The overall level of adaptive functioning accounted for a
significant proportion of the variance in HRQOL and may
also partly account for the difference in HRQOL betweenthis cohort and previous studies of PKU patients [8,9].
However, it also demonstrates that in disorders where de-
velopmental delay is observed, estimation and allowance
for adaptive functioning are important factors in clinical
management.
A broad spectrum of predominantly hyperkinetic
movement disorders were seen in this cohort. Not all
patients showed an anatomical defect on MRI, a rela-
tively small number showed basal ganglia changes. In
previous literature, it has been acknowledged that the
movement disorders in IEM are often associated with
basal ganglia dysfunction. This is however not necessary
observed anatomically, for example in neurotransmitter
disorders [21]. Of the four patients in our cohort who
showed basal ganglia abnormalities on MRI, three suf-
fered from an organic aciduria. Interestingly, all four
presented with dystonia as the predominant movement
disorder.
The limited number of publications addressing IEM
and movement disorders, coupled with the small num-
ber of cases in this cohort that had received treatment
targeting their movement disorder, suggests there may
be poor recognition of movement disorders in IEM pop-
ulations. Nonetheless, our results show that a more se-
vere movement disorder may be associated with a lower
overall quality of life and a larger developmental delay in
daily living skills. These results underscore the import-
ance of recognizing movement disorders in complex
childhood disorders like IEM.
An accurate diagnosis of a movement disorder is also
essential in the choice of therapeutic management and
likely efficacy of treatment. This factor was highlighted
in our cohort, with only five patients receiving treatment
for their movement disorder. Three of these were treated
with trihexyphenidyl and one with levodopa/carbidopa,
with a good symptomatic response reported in all cases.
The fifth was treated with pramipexol for her hypokine-
sia (frequently used in patients with AADC deficiency).
However, the specialists who analysed this patient’s video
felt that dystonia was also present, for which she re-
ceived no specific therapy.
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movement disorders. Besides disease-specific therapy
often additional symptomatic therapy is necessary. Ex-
amples of symptomatic therapies are trihexyphenidyl or
botulinum toxin for dystonia and clonazepam for myo-
clonus. Especially with the existence of these options
and development of novel symptom-specific treatments ,
for instance like deep brain stimulation for childhood
dystonia, an accurate clinical diagnosis by a specialist is
becoming increasingly important.
In our study, only patients with a suspected movement
disorder were asked to participate. Therefore it is not
possible to draw conclusions on the incidence of move-
ment disorders in this population. Also, the studied group
is heterogeneous and comprises patients with diverse and
severe disorders. In these patients the presence of move-
ment disorders is just one of the factors affecting the
HRQOL. The small sample sizes prevented subgroup ana-
lysis to differentiate the impact of type and severity of the
movement disorder from the wider complications of the
IEM upon HRQOL and adaptive functioning. A larger,
multi-centre study, comprising patients with and without
movement disorders, would be required to investigate this
further.
Furthermore, in this study we collected standardised
parental observations rather than self-reported assess-
ments by the children. Although self-reported data is
widely acknowledged to be preferential to proxy-reported
data, most participants (19/24) in this study were unable
to complete the questionnaires themselves. Previous stud-
ies found that when children may have communication or
cognitive deficits, parental reporting provides a useful al-
ternative tool [22].
Conclusions
This study demonstrates that HRQOL in children with
IEM and co-existent movement disorder is significantly
reduced compared to other chronic, stigmatizing disor-
ders. Delay in adaptive functioning and a more severe
movement disorder were associated with a lower HRQOL.
Accurate classification of movement disorders, particu-
larly in the context of complicated, multi-organ disorders,
is likely to aid therapeutic management, especially since
effective therapeutic options are available. We hope a
greater awareness of the presence of movement disorders
and targeted therapies might lead to improved motor
function and possibly subsequent overall quality of life.
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